E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
retinal detachment and the development of scarring (proliferative vitreoretinopathy) in patients with open globe trauma |
|
E.1.1.1 | Medical condition in easily understood language |
eyes that have suffered severe trauma due to undergo surgery to back of eye |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Eye Diseases [C11] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10057896 |
E.1.2 | Term | Proliferative vitreoretinopathy |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10038848 |
E.1.2 | Term | Retinal detachment |
E.1.2 | System Organ Class | 10015919 - Eye disorders |
|
E.1.3 | Condition being studied is a rare disease | Information not present in EudraCT |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
In patients who have sustained an open globe injury (severe trauma) and are undergoing vitrectomy surgery as a result(procedure to clear the gel in the back of the eye) , does the use of a steroid injection into and around the eye improve the visual outcome at 6 months? |
|
E.2.2 | Secondary objectives of the trial |
In patients who have sustained an open globe injury (severe trauma) and are undergoing vitrectomy surgery as a result(procedure to clear the gel in the back of the eye) , does the use of a steroid injection into and around the eye (a) reduce the proportion of patients in whom retinal detachment with scarring occurs at any timepoint within 6 months of the study surgery (b) increase the proportion of patients in whom stable complete retinal reattachment is achieved at 6 months post study surgery (c) increase the proportion of patients in whom stable central retinal reattachmen is achieved at 6 months post study surgery (d) decrease the proportion of patients in whom a tractional retinal detachment (no retinal hole) occurs at any timepoint within 6 months of the study surgery (e) reduce the number of operations required to achieve stable retinal reattachment (either complete or central) at 6 months after the study surgery (f) reduce the proportion of patients who suffer hypoton |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
The Adjuncts in Ocular Trauma (AOT Trial) From September 2011 - November 2013 (A pilot study using the same IMP in the target sample population to investigate any trends towards a treatment effect and power this definitive trial) |
|
E.3 | Principal inclusion criteria |
1. Adult subjects (Aged 18 years or over at the time of enrolment) 2. Full thickness, open-globe ocular trauma undergoing vitrectomy 3. Ability to give written informed consent 4. Willingness to accept randomization and attend follow-up for 6 months.
|
|
E.4 | Principal exclusion criteria |
1. Children (Age less than 18 years old at time of enrollment) 2. Pre-existing uncontrolled uveitis (This does not include patients whose uveitis is secondary to their injury or retinal detachment) 3. Definitive diagnosis of previous steroid induced glaucoma – (this does not include patients in whom a query of previous steroid-induced raised IOP has been postulated) 4. Pregnant or Breastfeeding females (Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control; true abstinence) from the time consent is signed until 6 weeks after completion of the trial. Females of childbearing potential must have a negative urinary pregnancy test within 7 days prior to being registered for trial treatment (Subjects are considered not of child bearing potential if they are permanently sterile (i.e. they have undergone a hysterectomy, bilateral tubal occlusion, or bilateral salpingectomy) or they are postmenopausal). 5. Allergy or previous known adverse reaction to triamcinolone acetonide 6. Inability to attend regular follow up. 7. Unable to give written informed consent. 8. Current or planned systemic corticosteroid use of a dose above physiological levels (e.g. >10mg prednisolone)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Dual primary outcome 1) Corrected visual acuity score (ETDRS letter score) at 6 months after initial study surgery 2) Proportion of patients with an improvement from baseline to 6 months of at least 10 on the corrected visual acuity (ETDRS letter score)
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Time-points of evaluation will be undertaken at baseline (prior to initial study surgery), three months after initial surgery and six months after initial surgery. |
|
E.5.2 | Secondary end point(s) |
To determine whether adjunctive intraocular and periocular steroid (triamcinolone acetonide) influences the development of scarring (proliferative vitreoretinopathy), retinal detachment, intraocular pressure abnormalities and other complications in eyes undergoing surgery for open globe trauma. In addition to assess the effects of treatment on quality of life measured using the EQ-5D, VFQ25 tools |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Time-points of evaluation will be undertaken at baseline (prior to initial study surgery), three months after initial surgery and six months after initial surgery. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Prmary outcome assessor masked/particpant masked/operating surgeon masked(until time IMP admin) |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 20 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 2 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 2 |